Paediatric Respiratory Reviews
Volume 11, Issue 3 , Pages 177-184 , September 2010

Early Eradication of Pseudomonas aeruginosa in Patients with Cystic Fibrosis

  • Bridget Stuart

      Affiliations

    • These two authors contributed equally to this work.
    • ,
  • Jenny H. Lin

      Affiliations

    • These two authors contributed equally to this work.
    • ,
  • Peter J. Mogayzel Jr.

      Affiliations

    • Corresponding Author InformationCorresponding author. Eudowood Division of Pediatric Respiratory Sciences, Johns Hopkins Hospital, 600 North Wolfe Street, Park 316, Baltimore, MD 21287-2533. Tel.: +410 955 2795; fax: +410 955 1030.

References 

  1. Andersen DH. Cystic fibrosis of the pancreas and its relationship to celiac disease; a clinical and pathological study. Am J Dis Child. 1938;56:344
  2. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073–1080
  3. Lee TW. Eradication of early Pseudomonas infection in cystic fibrosis. Chron Respir Dis. 2009;6(2):99–107
  4. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95(7):1005–1015
  5. Sagel SD, Sontag MK, Accurso FJ. Relationship between antimicrobial proteins and airway inflammation and infection in cystic fibrosis. Pediatr Pulmonol. 2009;44(4):402–409
  6. Pier GB, Grout M, Zaidi TS, et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science. 1996;271(5245):64–67
  7. Downey DG, Bell SC, Elborn JS. Neutrophils in cystic fibrosis. Thorax. 2009;64(1):81–88
  8. Tabary O, Corvol H, Boncoeur E, et al. Adherence of airway neutrophils and inflammatory response are increased in CF airway epithelial cell-neutrophil interactions. Am J Physiol Lung Cell Mol Physiol. 2006;290(3):L588–L596
  9. Tang H, Kays M, Prince A. Role of Pseudomonas aeruginosa pili in acute pulmonary infection. Infect Immun. 1995;63(4):1278–1285
  10. Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Respir Care. 2009;54(5):628–640
  11. Hybiske K, Ichikawa JK, Huang V, et al. Cystic fibrosis airway epithelial cell polarity and bacterial flagellin determine host response to Pseudomonas aeruginosa. Cell Microbiol. 2004;6(1):49–63
  12. Cobb LM, Mychaleckyj JC, Wozniak DJ, et al. Pseudomonas aeruginosa flagellin and alginate elicit very distinct gene expression patterns in airway epithelial cells: implications for cystic fibrosis disease. J Immunol. 2004;173(9):5659–5670
  13. Davies DG, Parsek MR, Pearson JP, et al. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science. 1998;280(5361):295–298
  14. Singh PK, Schaefer AL, Parsek MR, et al. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000;407(6805):762–764
  15. Landry RM, An D, Hupp JT, et al. Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance. Mol Microbiol. 2006;59(1):142–151
  16. Gillis RJ, White KG, Choi KH, et al. Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2005;49(9):3858–3867
  17. Burns J, Gibson R, McNamara S, et al. Longitudinal Assessment of Pseudomonas aeruginosa in Young Children with Cystic Fibrosis. The Journal of Infectious Diseases. 2001;183(3):444–452
  18. Armstrong DS, Grimwood K, Carlin JB, et al. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol. 1996;21(5):267–275
  19. Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol. 1999;28(5):321–328
  20. Ramsey BW, Wentz KR, Smith AL, et al. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis. 1991;144(2):331–337
  21. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16(4):749–767
  22. Hollsing AE, Granstrom M, Vasil ML, et al. Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis. J Clin Microbiol. 1987;25(10):1868–1874
  23. da Silva Filho LV, Tateno AF, Martins KM, et al. The combination of PCR and serology increases the diagnosis of Pseudomonas aeruginosa colonization/infection in cystic fibrosis. Pediatr Pulmonol. 2007;42(10):938–944
  24. Brett MM, Ghoneim AT, Littlewood JM. Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study. J Clin Microbiol. 1988;26(8):1565–1570
  25. Pressler T, Frederiksen B, Skov M, et al. Early rise of anti-pseudomonas antibodies and a mucoid phenotype of pseudomonas aeruginosa are risk factors for development of chronic lung infection--a case control study. J Cyst Fibros. 2006;5(1):9–15
  26. Karpati F, Jonasson J. Polymerase chain reaction for the detection of Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia in sputum of patients with cystic fibrosis. Mol Cell Probes. 1996;10(6):397–403
  27. da Silva Filho LV, Tateno AF, Velloso LF, et al. Identification of Pseudomonas aeruginosa, Burkholderia cepacia complex, and Stenotrophomonas maltophilia in respiratory samples from cystic fibrosis patients using multiplex PCR. Pediatr Pulmonol. 2004;37(6):537–547
  28. Xu J, Moore JE, Murphy PG, et al. Early detection of Pseudomonas aeruginosa--comparison of conventional versus molecular (PCR) detection directly from adult patients with cystic fibrosis (CF). Ann Clin Microbiol Antimicrob. 2004;3:21
  29. Spilker T, Coenye T, Vandamme P, et al. PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients. J Clin Microbiol. 2004;42(5):2074–2079
  30. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001;138(5):699–704
  31. Maselli JH, Sontag MK, Norris JM, et al. Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr Pulmonol. 2003;35(4):257–262
  32. Ratjen F, Comes G, Paul K, et al. Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol. 2001;31(1):13–16
  33. Cystic Fibrosis Foundation: Patient Registry 2008 Annual Report. Bethesda, MD. 2009.
  34. Høiby N, Flensborg EW, Beck B, et al. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand J Respir Dis. 1977;58(2):65–79
  35. Høiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response. Acta Pathol Microbiol Scand B Microbiol Immunol. 1974;82(4):551–558
  36. Lee TW, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29–34
  37. Schaedel C, de MI, Hjelte L, et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol. 2002;33(6):483–491
  38. Parad RB, Gerard CJ, Zurakowski D, et al. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun. 1999;67(9):4744–4750
  39. Aebi C, Bracher R, Liechti-Gallati S, et al. The age at onset of chronic Pseudomonas aeruginosa colonization in cystic fibrosis--prognostic significance. Eur J Pediatr. 1995;154(9 Suppl 4):S69–S73
  40. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91–100
  41. Ballmann M, Rabsch P, von der HH. Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax. 1998;53(9):732–737
  42. Littlewood JM, Miller MG, Ghoneim AT, et al. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet. 1985;1(8433):865
  43. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991;338(8769):725–726
  44. Vazquez C, Municio M, Corera M, et al. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Acta Paediatr. 1993;82(3):308–309
  45. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997;23(5):330–335
  46. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol. 1998;25(2):88–92
  47. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet. 2001;358(9286):983–984
  48. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003;167(6):841–849
  49. Gibson RL, Emerson J, Mayer-Hamblett N, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol. 2007;42(7):610–623
  50. Taccetti G, Campana S, Festini F, et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J. 2005;26(3):458–461
  51. Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros. 2008;7(6):523–530
  52. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2009;4:CD004197
  53. Ratjen R, Stenglein S, Munck A. Inhaled tobramycin nebulizer solution for treatment of early Pseudomonas aeruginosa infection: the ELITE study. J Cyst Fibros. 2008;7(Suppl 2):S26
  54. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. Early Anti-Pseudomonal Acquisition in Young Patients with Cystic Fibrosis: Rationale and Design of the EPIC Clinical Trial and Observational Study. Contemp Clin Trials. 2009;
  55. Proesmans M, Boulanger L, Vermeulen F, et al. Eradication of Recent Pseudomonas aeruginosa isolation: TOBI versus colisitin/ciprofloxacin. Pediatr Pulmonol. 2009;(Suppl 32):321
  56. Wainwright C, Carlin J, Cooper P, et al. Australasian cystic fibrosis BAL study interim analysis. Pediatr Pulmonol. 2006;(Suppl 29):317
  57. Steinkamp G, Tummler B, Malottke R, et al. Treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Arch Dis Child. 1989;64(7):1022–1028
  58. Kesser KC, Geller DE. New aerosol delivery devices for cystic fibrosis. Respir Care. 2009;54(6):754–767
  59. Mallol J, Rattray S, Walker G, et al. Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol. 1996;21(5):276–281
  60. Chua HL, Collis GG, Newbury AM, et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J. 1994;7(12):2185–2191
  61. Weber A, Smith A, Williams-Warren J, et al. Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol. 1994;17(5):331–339
  62. Eisenberg J, Pepe M, Williams-Warren J, et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest. 1997;111(4):955–962
  63. Weber A, Morlin G, Cohen M, et al. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol. 1997;23(4):249–260
  64. Mendelman PM, Smith AL, Levy J, et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis. 1985;132(4):761–765
  65. Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J Cyst Fibros. 2009;8(5):295–315
  66. Steinkamp G, Tummler B, Gappa M, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol. 1989;6(2):91–98
  67. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993;122(1):1–9
  68. Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007;151(2):134–139139
  69. McPhail GL, Acton JD, Fenchel MC, et al. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr. 2008;153(6):752–757
  70. Nilsson E, Larsson A, Olesen HV, et al. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol. 2008;43(9):892–899
  71. Johansen HK, Gotzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2008;(4):CD001399
  72. Ratjen F, Munck A, Kho P, et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010;65:286–291

PII: S1526-0542(10)00039-4

doi: 10.1016/j.prrv.2010.05.003

Paediatric Respiratory Reviews
Volume 11, Issue 3 , Pages 177-184 , September 2010

Article Tools

* Image Usage & Resolution